rare diseases

relay
Biotech

Rallybio shifts gears, cashing out of Recursion pact

Rallybio has swerved away from its Recursion pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway.
Nick Paul Taylor Jul 8, 2025 8:59am
Graphic image of an arrow nailing the bullseye of a target

Cogent hits primary endpoint, building case for Blueprint rival

Jul 7, 2025 9:16am
Congress senate house government US
Favicon Fierce Pharma

Senate revives Orphan Cures Act in Trump's tax bill

Jun 30, 2025 10:09am
ice skate on the ice

Minovia skates SPAC-wards into public market

Jun 25, 2025 10:33am
Cartoon of businessmen standing around a broken target

Vigil's rare brain disease drug flunks phase 2 study

Jun 4, 2025 9:45am
Sanofi
Favicon Fierce Pharma

Sanofi buys Blueprint for $9.1B, its largest deal in 7 years

Jun 2, 2025 11:09am